Modalis' CRISPR-GNDM technology can activate or repress any gene in a controlled manner without the need for DNA cuts. This alliance also creates significant opportunities for Modalis to establish additional strategic partnerships.
Ginkgo Technology Network, an ecosystem of technology partners, is dedicated to driving innovation in our customers' research and development programs. The Technology Network brings together a diverse group of partners across AI, genetic medicine, biologics, and manufacturing, integrating each partner's capabilities to provide customers with robust end-to-end solutions for successful research and development outcomes. is intended to provide.
Modalis is a pioneer in CRISPR-based epigenome modulation technology, developing therapeutics for patients suffering from serious genetic diseases, including neuromuscular diseases, CNS, and cardiomyopathy.
Haru Morita, CEO of Modalis, said: We believe that the technology provided by Ginkgo and our proprietary epigenome modulation technology will be complementary in a wide range of areas, including the discovery and diagnosis of targeted disease genes and the development of new cell and gene therapies. This collaboration not only makes our proprietary technology available to a wider range of companies, but also provides additional opportunities for Modalis to establish direct strategic alliances with companies interested in developing new treatments for serious diseases. is born. ”
Anna Marie Wagner, Senior Vice President, Head of AI and Corporate Development at Ginkgo, said: “We believe Modalis' unique epigenome modulation technology provides an attractive platform for competitiveness in a wide range of fields, as well as the development of new cell and gene therapies.” Food, Agriculture, Diagnostics, Specialty Chemicals We will contribute to the expansion of markets such as We are excited to have Modalis join her Ginkgo technology network. Their participation has the potential to add significant value to our extensive biotechnology customer base. ”
See more ginkgo news
Ginkgo Bioworks recently acquired AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, associated functional data and metadata, and AgBiome's development pipeline. Acquired.
